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are also classified as complicated UTIs.
addition,  UTIs  in  male patients  and  infections  caused  by  multidrug  resistant  bacteria 
transplant  (viii), immunosuppression  caused  by  diseases  or  medicines  [5],  [9].  In 
(vi) presence of an indwelling urethral catheter stent or nephrostomy tube, (vii) a renal 
obstruction, (ii) a polycystic kidney, (iii) diabetes, (iv) pregnancy, (v) a neurologic bladder, 
the  following  underlying  diseases  or  risk  factors  are  present:  (i)  a  urinary  tract 
those occurring in otherwise healthy individuals. UTIs are by definition complicated if 
patient’s  underlying  disease  and  other  risk  factors  present.  Uncomplicated  UTIs  are 
UTIs can also be divided into uncomplicated and complicated infections based on the 
(epididymitis)  may  be  affected  in some cases of  lower UTIs in men [10].
backache  and  nausea  [9]. Additionally,  the  prostate  (prostatitis)  or  epididymis 
suprapubic  pain  and  hematuria,  patients  suffering  with  pyelonephritis  present  fever, 
While patients suffering with cystitis often present dysuria, voiding urgency, nocturia, 
(pyelonephritis) (Figure 1) [8]. The symptoms of lower and upper UTIs are different. 
consists  of infections  of the  upper  urinary  tract,  particularly  the  kidneys 
of the lower urinary tract, bladder (cystitis) and urethra (urethritis). The second group 
Anatomical  classification divides UTIs  into two groups. The first group are infections 
additional complications [5]–[8].
important for defining an accurate (potential) antibiotic therapy and to avoid the risks of 
risk  factors,  the  severity  grade,  and  microbiological  findings.  Classification  is 
UTIs  are  classified based on  the  anatomical site of  infections, the patient’s  underlying 
episode during their lifetime [2]–[4].
UTIs  is high  and  it  is  estimated  that  one  in  three  women  will  have  at  least  one  UTI 
the urinary  tract  or  with  prostate  diseases.  In  contrast,  in  women  the  frequency  of 
of UTIs in men until 65 years of age is low and often associated with abnormalities in 
[2]. Age-specific sex-related differences in infections rates are observed. The incidence 
hospitals  and  the  community,  affecting  around  150  million  people  worldwide  [1], 
Urinary tract infections (UTIs) are among the most common bacterial infections in both 
Urinary tract Infections
General Introduction
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1Complicated UTIs can lead to more severe infections such as febrile UTIs and 
urosepsis and are more difficult to treat. In general, uncomplicated UTIs, mostly 
community-acquired (CA), are self-limiting and will only be treated with 
antimicrobial therapy if lasting longer than three days. Hospital-acquired (HA) or 
nosocomial UTIs are often complicated and it is estimated that 80% is related to 
indwelling catheters [11][12]. During long catheterization, bacteria form a biofilm in the 
catheter, facilitating its entrance into the lower urinary tract and enhancing 
dissemination to the upper urinary tract where they are more difficult to treat [13].
Overall, catheter-associated UTIs (CAUTIs) are associated with increased morbidity and 
mortality and are often caused by multidrug resistant bacteria [12], [14], [15]. Other risk 
factors associated with HA-UTIs include surgery (of  the urinary tract), patients suffering 
from diabetes and other comorbidities, and previous admission to a hospital, i.e., between 
six months and 14 days prior to the current admission [16], [17]. HA-UTIs represent 
approximately 35-45% of  nosocomial infections and lead to an increase in the morbidity, 
mortality and emotional suffering of  hospitalized patients [16].      
4
in the different locations affected during bacterial UTIs.
(urethra and bladder) are classified as urethritis and cystitis. The green  circles represent the bacteria 
tract  (kidneys)  are  classified as  pyelonephritis  and  infections  affecting  the  lower  urinary  tract 









from the host fecal flora [25] due to the short proximity between urethra and anus in
factor in the pathogenesis of  UTIs. It is believed that most UTI-causing strains originate 
The ability of ExPEC to survive and colonize in the gastrointestinal tract is an important 
healthy individuals and for causing infections in other body sites [23], [24].
factors  is  essential for  both  ExPEC’s  ability  to  survive  in  the  gastrointestinal  tract  of 
toxins and genes involved in the iron uptake systems. The presence of these virulence 
genome  with  a higher number of virulence genes, mainly adhesins, invasins, fimbriae, 
different parts of the human body and have, compared to commensal E. coli, a bigger 
agent [21],  [22]  causing  around  80%  of UTIs.  Particularly,  ExPEC  can  colonize 
can be  caused  by  several  microorganisms, E.  coli being  the  most  common  etiological 
two different groups: intestinal (InPEC) and extraintestinal E. coli (ExPEC) [20]. UTIs 
tract, however there are also pathogenic strains. Pathogenic E. coli can be divided into 
Escherichia coli are known as part of the normal microbiota of the human gastrointestinal 
  etiological agent of  UTIs
Extra intestinal pathogenic Escherichia coli as common
specific patient groups and the etiological agent causing the infection [19].
choice  of  antimicrobial  therapy  further  depends  on  the  presentation  of  infections, 
fluoroquinolones and  beta-lactams  are  recommended  for  pyelonephritis  [6],  [22].  The 
including  amoxicillin-clavulanate can be used to treat acute uncomplicated cystitis and 
norfloxacin  and  ofloxacin  as  alternatives  [21],  [22].  In  addition,  beta-lactams 
are the  first-choice  antibiotics  for  adult  patients,  using  ciprofloxacin,  levofloxacin, 
is required,  however,  fosfomycin,  nitrofurantoin  and  trimethoprim-sulfamethoxazole 
Treatment with antibiotics is not recommended for asymptomatic UTIs. If treatment 
cfu/mL for acute uncomplicated pyelonephritis in women [4], [15].
clinically relevant  threshold  is  103 cfu/mL  for  acute  uncomplicated  cystitis  and  104 
higher risk  of   developing  UTIs  (e.g.,  pregnant  women  and  catheterized  patients)  the 
colony forming  units  (cfu)/mL  as  threshold  [18].  However,  in  patient  groups  with  a 
UTIs is  the  detection  and  identification  of  pathogens  through  urine  culture,  with  105 
and  are,  therefore,  being  easier  diagnosed.  The  gold  standard  for  the  diagnosis  of 
and bacteria. About 50% of women suffering from UTIs present with clinical symptoms 
urine, such as products of normal and abnormal metabolism, cells, cellular fragments, 
chemical,  and  microscopic  tests  that  detect  and/or  measure  several  substances  in  the 
physical examination  and  by  using  laboratory  tests  as  urinalysis,  a  group  of physical, 
the  urine  in  the absence of symptoms, to severe urosepsis. Diagnosis is done through 
Symptoms  of UTIs  vary  from  asymptomatic  bacteriuria,  the  presence  of bacteria  in 




essential to overcome the iron limitation in the host environment such as urine [32].
kidneys [29]–[31]. Finally, the iron uptake systems such as aerobactin or siderophore are 
fimbriae  and  F1C  interact  with  the  host  cells  present  in  the  low urinary  tract  and 
isolates  leading  to  the  development  of  pyelonephritis  [29]. Other  fimbriae  such  as  S 
urothelial  cells.  The  presence  of  P  fimbriae  is  associated with  ascension  of  UPEC 
enhanced  survival  of E.  coli in  the  urinary  tract  and are  also  involved  in  invasion  of 
that  bind  urothelial  mannosylated  glycoproteins are  known  to  be  associated  with  the 
adhesins, critical for binding to the cells of the urinary  tract  [28,  56]. Type  1  fimbriae 
bacterial cell surface as, e.g., outer membrane proteins, including fimbria, pili, curli and 
two types of virulence factors. The first type consists of  virulence factors located on the 
a specific group, named uropathogenic E. coli (UPEC) has been defined. UPEC contain 
overcome the host’s defense strategies (Figure 2). Among ExPEC associated with UTIs 
microorganisms  [27]. E.  coli causing UTIs  contain  specific  virulence  factors  to 
antimicrobial  peptides to  prevent  the  colonization  and  infection  caused  by 
mechanisms such as the iron limitation in the urine, specific antibodies, or presence of 
virulence factors  in  the E.  coli bacterium.  The  human  host  has  several  defense 
The  severity  of  UTIs  depends  on  both  host  factors  and  the  presence  of  specific 
damage may occur, increasing the risk of  bacteremia/septicemia [26].
easily  translocated  by host  cells.  Subsequently,  kidney  colonization  and  host  tissue 
urothelial  cells  the uropathogens can gain access to additional nutrients and be more 
the  resurgence  of the  intracellular  pathogens  [28],  [45].  In  addition,  by  invading  the 
These  reservoirs are  therefore  associated  with  recurrent  and  chronic  UTIs  caused  by 
where  they can  persist  being  protected  against  the  host-defense  mechanisms  [57]. 
bladder intracellular  bacterial  communities  (IBCs)  or  quiescent  intracellular  reservoirs 
coli can  form  biofilms  and/or  invade  epithelial  cells  and  replicate  herein  forming 
to  the  surface  and  interaction  with  bladder  epithelium.  After  these  three  steps, E. 
colonization, (ii) bladder ascension and growth of  planktonic cells in urine, (iii) adherence 
The  pathogenesis  of E.  coli causing  a UTI  exists  of   the  following  steps:  (i)  urethra 






            
 
conmodification [43].moietysiderophoresalmochelin-likeataining
and IIb, and linear  microcins, e.g. H47 and M, that carry a C-terminal posttranslational 
can  be further  subdivided  into  IIa, those  containing  disulfide  bonds, e.g. V  
kDa, e.g. B17 and C7, and Class II microcins ranging from 5 to 10 kDa. Class II microcins 
classified into Class I microcins that include the peptides with a molecular mass below 5 
was  also  identified  among  avian  pathogenic E. coli strains  [41]. Microcins  can  be  
microcin is encoded by a heterogeneous group of  large virulence related plasmids, that 
Microcin  V has  been  frequently  identified  in  UPEC  causing  pyelonephritis  [35].  This 
age in which the cell cycle is arrested and DNA repair and mutagenesis is induced [42]. 
and are not induced by the SOS system, responsible for a global response to DNA dam- 
to siderophores [41]. Different from colicins, microcins are post-translationally modified 
Microcins are low molecular weight peptides produced by UPEC and some are related 
molecular synthesis, or damaging bacterial DNA through their nuclease activity [38], [40].
nisms as, e.g., disrupting the bacterial membrane by forming a pore, interrupting macro- 
large plasmids and are not secreted [38], [39]. Colicins present different action mecha- 
by small plasmids and released into the medium, while group B colicins are encoded by 
group B colicins use the TonB system. In addition, group A colicins are normally encoded 
into group A and group B. The group A colicins are translocated by the Tol system and 
microcins are the bacteriocins mostly associated with UPECs. Colicins can be classified 
with limited nutrients and therefore increase its virulence potential [35], [37]. Colicins and 
ing produced [35]. They may help UPEC to outcompete other bacteria in an environment 
related bacteria [35], [36], are well-known. Usually multiple, different bacteriocins are be- 
Among the secreted virulence factors, bacteriocins, antibacterial peptides that kill closely 
with pyelonephritis and toxicity against urinary tract cells [33], [34].
polymorphonuclear phagocytosis and death of  bladder epithelial cells. SAT is associated 
erythrocytes and contributes to nephropathogenecity, while the CNF-1 interferes with 
the urinary tract. The alfa-hemolysin (HlyA) is a pore-forming toxin that affects mainly 
and secreted autotransporter toxin (SAT) play an important role in the colonization of 
by UPEC such as the alfa- hemolysin (HlyA), cytotoxic necrotizing factor type 1 (CNF1)
age effector immune cells and access host nutrients and iron stores [29]. Toxins secreted 
poproteins that can lyse host cells, allowing UPEC to easier cross mucosal barriers, dam- 
The second group of  virulence factors consists of  secreted proteins such as toxins and li- 
[38].
stationary phase of  the growth, anaerobiosis, high temperature and nutrient depletion 
gent  response,  catabolize  repression,  mutations  in  specific  genes,  e.g.  the ompR gene, 
the gut of  animals.  Its production is stimulated by several factors,  including the strin- 
Bacteriocin production is widely distributed in nature and is particularly observed in 
phylogenetically associated [41].
Interestingly,  the  microcin  V  and  M, from  the  IIa  and  IIb  class,  respectively,  are 
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Overall, the production of  bacteriocins are associated with E. coli strains belonging to 
phylogenetic group B2 present in human fecal samples. Interestingly, most ExPEC 
isolates belong to this phylogenetic group [44]. Overall the profile of the virulence 
factors in UPEC isolates is highly diverse and, for this reason, establishing a relation 
between the presence of virulence factors and severity of the infections is difficult. Still, 
identifying virulence factors could be used to search for molecular markers for more 
accurate diagnostics and as potential vaccine targets [45].
Figure 2. Virulence factors of  uropathogenic Escherichia coli. The virulence factors can be divid-
ed into four main groups: adhesins and fimbriae, both associated with the adhesion of the 
bacteria to host urothelial cells; iron acquisition proteins, essential to survive in and to colonize 
the urinary tract in an iron limited environment; and toxins, associated with immune evasion, 




Crucial for the persistence of E. coli in the genitourinary tract is the ability to form 
a biofilm [46] and it is estimated that 68-80% of E. coli can do so [47]–[49]. Bacterial 
cells present in biofilm are known to have increased resistance to antibiotics, detergents 
and host immune defense substances [46], [50]. UPEC can form an intracellular biofilm 
community (IBC) in urogenital cells and a biofilm on abiotic surfaces of indwelling 
medical devices, including urinary catheters [51]. Therefore, CAUTIs are one of  the 
most common nosocomial infections [13], [52]. E. coli can also form biofilms into the 
bladder walls[51]. Biofilm formation hinders the treatment of UTIs, as they “protect” 
the bacteria against the antibiotic therapy, and is, therefore, also associated with chronic 
UTIs, such as chronic prostatitis [51], [53]. Indeed, prolonged catheterization can 
result in persistent infections and inevitable lead to bacteriuria. Catheters also impair 
the normal defense of the bladder, further increasing bacterial colonization. Moreover, 
bacteria in biofilms work as a community, facilitating the exchange of genetic material 
thereby facilitating the spread of antibiotic resistance. Finally, biofilms complicate an 
accurate diagnosis and antibiotic susceptibility testing as only the bacteria floating in the 
urine will be collected. The most effective way to avoid CAUTIs is to prevent 
catheterization or reduce the duration of it [22], [54]. This also reduces the reservoir 
of  MDR gram-negative bacteria inside hospitals [55].
Mobile genetic elements
Many of  the virulence factors are encoded by genes on mobile genetic elements 
(MGEs), especially pathogenicity islands (PAIs). PAIs are a distinct class of  genomic 
islands that are usually absent from nonpathogenic microorganisms. They are 
horizontally acquired and can originate from non- related microorganisms. PAIs are 
considered to be involved in ExPEC’s pathogenicity and play a role in the evolution of 
hypervirulent E. coli clones [58], [59]. Virulence genes present in PAIs include 
adhesins, toxins, invasins, capsule genes, and genes belonging to the iron uptake 
system and secretion system [61]. The PAIs are characterized by tRNA genes, GC-
content, repeated sequences and insertion sequences (ISs) [58], [62]. UPECs can have 
several PAIs and there is an association be-tween the presence of  PAIs and the severity 
of  infections [63].
Also, plasmids containing genes encoding bacteriocin, toxins, genes belonging to the 
iron uptake systems and outer membrane protein genes, have been associated 
with virulence in ExPEC, particularly extended-spectrum-beta-lactamase(ESBL)-
encoding plasmids belonging to the IncF, A/C, N, and K types[66]. The 
acquisition of plasmids is further associated with bacteria causing outbreaks and 
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other virotypes are more restricted to specific regions [79].
virotype C being the most prevalent showing a worldwide dissemination [77], [78]. The 
virulence  genes,  the  ST131 E.  coli can  be  divided  into  virotypes  A,  B,  C  and D,  with 
spread  worldwide  in the  recent  years  [77].  By  analyzing  the  presence  of  specific 
resistant  to  fluoroquinolones  and  cephalosporins  and  producing  CTX-M-15,  rapidly 
Especially,  a specific  subgroup,  assigned  as H30-Rx,  mostly  associated  with  isolates 
presence of the type 1 fimbriae encoded by the fimH30 gene (ST131 sub-clone H30). 
sion  of   one  of   the  sub-clones  of   this  lineage  was  shown  to  be  driven  by  the 
nant clone since the beginning of  the third millennium [75], [76]. The successful expan- 
studied high-risk clone of E. coli is the ST131 lineage, which became a worldwide domi- 
abundant  in  the community and  in  the hospital  environment.  One  of the most often 
a MDR- phenotype with increased levels of virulence. Such high-risk clones are highly 
Isolates belonging to successful lineages are also called high-risk clones and often display 
antibiotic groups in that regions [72]–[74].
profiles are associated with particular geographical regions related to the use of specific 
sion and rapid dissemination of specific lineages with specific antibiotic resistance gene 
emergence of specific E. coli lineages. It is strongly suggestive that the emergence, expan- 
of  the CTX-M-15 gene, is being observed since early 2000s and is associated with the 
tamase,  CTX-M  gene  [70],  [71].  The  spread  of   these  resistance  genes,  especially  that 
ESBL-producing E. coli in Europe and the Americas, 97% contains a class A beta-lac- 
are of big concern [68] and empirical treatment of UTIs is challenging [69]. Among the 
reported [1]. Indeed, UTIs with ESBL- producing and fluoroquinolones resistant E. coli 
use of last-resort antibiotics as carbapenems for which also increasing resistant rates are 
losporins to treat UTIs cannot be used against such resistant bacteria, necessitating the 
has  increased  worldwide. Commonly used  antibiotics  as  fluoroquinolones and cepha- 
In the last years, the number of infections caused by multidrug-resistant (MDR) E. coli 
Antibiotic resistance and E. coli high-risk clones
genes contributing to the virulence of  ExPEC [60].
Finally, other MGEs as transposable elements and bacteriophages may contain virulence 
Chapter 1
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treating UTIs caused by  MDR E. coli [87]–[89].
treat  uncomplicat- ed  UTIs  and  recent  studies  indicated  it  to  be  a  good  choice  for  
necrosis [86]. Despite  the  presence  of  side  effects, fosfomycin  has  been  used  to  
have  been reported such as angioedema, aplastic anemia, cholestatic jaundice and hepatic 
limited   effectiveness  in  patients  who  are  critically   ill   [86].  Additionally,  side   effects   
for a while  mainly  due  to  the  poor  bioavailability  of  oral  fosfomycin  (37%) and  its  
it  has  low resistance rates  (1- 5%) and works against  biofilms, the drug was not  used  
1969 in Spain and is active against both Gram-positive and -negative bacteria. Although, 
and ESBL- and carbapenemase-producing bacteria [85]. Fosfomycin was discovered in 
studied  and  used  to  treat  infections  caused  by  thrimetoprim-sulfametazaxole  resistant 
With  the  increase  of   antibiotic  resistance,  old  drugs,  including  fosfomycin  have  been 
Fosfomycin (hetero)resistance
prevent further spread of  antibiotic resistance.
prevention measures, and extensive surveillance are extremely important and required to 
proved diagnostic methods (including the detection of  these high-risk clones), infection 
be treated at all [68]. Furthermore, a better choice of  current antimicrobial agents, im- 
crises. It is estimated that already 700,000 people per annum die of  infections that cannot 
spread of  highly virulent and resistant clones is even enhancing the antibiotic resistance 
reduce  the  abusive  use  of   it.  The  combination  of   the  abusive  antibiotic  use  and  the 
In Brazil, antibiotics are available even without prescription, despite laws to control and 
most important mechanism for spread of  antibiotic resistance [84].
[83]. Overall, plasmid mediated horizontal gene transfer (HGT) is considered to be the 
replicon types such as FIA, FIB and FII, and have the ability to carry resistance cassettes 
nated among the whole family of  Enterobacteriacea. These plasmids contain  divergent 
incompatibility group IncF are known to often carry resistance genes and are dissemi- 
important role in the spread of  resistance genes [67]. Especially, plasmids belonging to 
chapter to be important for acquisition of  genes encoding virulence factors also play an 
to trimethoprim in different countries including Brazil. MGEs already discussed in these 
ducing clones [82]. In addition, ST69 has been associated with the increase of  resistance 
these lineages, stressing the importance of  monitoring the emergence of  new ESBL-pro- 
production [81]. However, recent studies reported ESBL-producing isolates belonging to 
worldwide [80]. Most ST69 and ST73 isolates are normally not associated with ESBL 
Next to ST131, other lineages as ST69, ST73, ST405 and ST648 successfully expanded 
General Introduction   
Fosfomycin acts by inhibiting the first cytoplasmic stage of cell wall synthesis by binding 
to the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) thereby in-
hibiting its activation. To enter the bacteria, fosfomycin uses two different transporters, 
L-alpha-glycerol-3-phosphate (GlpT) and hexose-6-phosphate (UhpT) [85]. The activity
of  the second transporter is induced by the presence of  glucose-6-phosphate. In addi-
tion, expression of  both transporters is regulated by cyclic AMP (cAMP) [90]. Further-
more, fosfomycin can reduce the adhesion of  the bacteria to the epithelium [91] (Figure
3). Although both the mechanism of action of fosfomycin and its structure are unique,
making cross-resistance unusual, resistance to fosfomycin can occur through several oth-
er mechanisms. The best known is a mutation in the murA gene resulting in an amino
acid change of  a cysteine into an aspartate found in several bacteria like Vibrio ischeri,
Chlamydia spp. and Mycobacterium tuberculosis [91] and due to which fosfomycin cannot bind
to MurA any longer. Another resistance mechanism is the production of  peptidoglycan
via an alternative route, as has been identified in Pseudomonas putida (recycling route) [92].
In E. coli, fosfomycin resistance has been described to be caused by mutations in the 
chromosomally located glpT and uhpT genes encoding fosfomycin transporters resulting 
in blocking the uptake of  fosfomycin [93]. Since these proteins are also essential for 
bacterial survival and their metabolism, such mutations are rarely found. More commonly 
found mutations include those in the cyaA and ptsI genes, resulting in lower cAMP levels 
thereby decreasing the expression of  fosfomycin transporters. In addition, the overex-
pression of  MurA is also related to fosfomycin resistance in E. coli [93], [94].
Enzymes capable of  modifying fosfomycin, such as glutathione S-transferase (FosA), a 
metalloenzyme transferred through plasmids among Enterobacteriacea, can also cause 
fosfomycin resistance. Several subtypes of  glutathione S-transferases with similar struc-
tures have been described (FosA2, FosA3, FosA4 and FosA5) [95], [96]. Other enzymes 
involved in fosfomycin resistances include FosB, an enzyme 46% identical to FosA and 
catalyzing a reaction between cysteine and fosfomycin in Gram-positive bacteria, FosX, 
a chromosomal enzyme catalyzing a reaction of  fosfomycin with water and found in 
Listeria monocytogenes, and FosC, an enzyme similar to glutathione S-transferase catalyzing 






cAMP-CRP complex and UhpA.
using UDP-GlcNAc  and  PEP. The  expression  of  the glpT and uhpT genes  are  induced  by  the  
consequently, the  formation  of  UDP-GlcNac-3-O-enoulpyuvate  a  peptidoglycan  precursor  
by both GlpT and UhpT. Once inside the cell, fosfomycin binds to MurA blocking the catalysis and, 
Figure 3. Fosfomycin uptake and regulation of  transporters. Fosfomycin can be transported 
subpopulations survive and may cause  persistent and recurrent UTIs [103].
the  urothelial  cells. However,  due  to  the  heteroresistance  phenotype, resistant  
fosfomycin penetrates cells,  it normally kills the bacteria in these IBCs present inside  
[102], and  may  be  particularly  relevant  for  UTIs  where  bacteria  form  IBCs. Once  
normally  not  revers ible  [101]. Heteroresistance  can  lead  to  treatment  failure  [100], 
minimum inhibitory  concentration (MIC) [100]. In addition, a heteroresistant profile is 
able  to  growth in   the  presence  of  concentrations  of  the  antibiotic  higher  than their  
presence of  one  or more subpopulations in a particular bacterial population that is/are 
from  such   tolerant  subpopulations, heteroresistant  strains  can  be  defined  as  the  
antibiot ics  but  that  are  not  detected  in  routine  diagnostics  [100]. However, different  
relatively  common, and can generate subpopulations that tolerate high concentrations of  
not fully  clear  and  standardized. The  heterogenicity  inside  a  bacterial  population  is  
may   be   an   underestimated   problem.  The   precise   definition   of   heteroresistance   is   
Even though the fosfomycin resistance rate remains low, heteroresistance to fosfomycin 
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Heteroresistance to fosfomycin has been described for S. pneumoniae, P. aeruginosa and E. 
coli [89], [94], [97][90], [102]. Previous studies have linked this phenotype to mutations in 
genes that regulate cAMP, ptsI and cyaA genes, in genes encoding transporters used by 
fosfomycin, i.e., glpT and uhpT, in genes that regulate the expression of  these transport-
ers such as glpR, uhpA, uhpB, uhpC, resulting in reduced expression of  the transporters 
used by fosfomycin and consequently its uptake, and mutations in the fosfomycin 
target murA gene, preventing the binding of  fosfomycin to its active site. However, 
the few studies addressing these mechanisms state that such mutations come with a 
high cost of bacterial fitness being the reason that the frequency of heteroresistance is 
even lower than full resistance [90], [102], [104]–[106]. Clearly, studies evaluating the 
clinical impact of heteroresistance against fosfomycin and the mechanisms leading to 
this phenotype are highly relevant for a better understanding of the importance of this 











ed  from  patients  in  four  hospitals  in  Rio  de  Janeiro,  Brazil 
the population structure of E. coli from urine samples collect- 
which had as main objective to comprehensively characterize 
These  questions  were  addressed  in  chapter  2  of   this  thesis 
associated with specific lineages?
lates in Brazil? What is the frequency of  antibiotic resistance? and Could resistance be 
Thus, our initial research questions were: How is the population structure of these iso- 
regions is key for developing infection prevention strategies.
ticularly Brazil. Therefore, getting insight into the local epidemiology of E. coli in these 
in  several  countries,  there  is  a  lack  of   information  for  South  American  countries,  par- 
an association between specific sequence types and the resistance profile has been found 
tance rates to antibiotics normally used to treat these infections are observed. Although 
As mentioned, E. coli is the most common etiological agent of  UTIs and increased resis- 
prevention strategies.
their epidemiology. This knowledge is key for improvement of treatment and infection 
derstand  the  evolution  and  transmission  of high-risk  bacterial  clones  and  understand 
the risk of emerging pathogens, predict epidemiological patterns, comprehensively un- 
of  bacterial  pathogens,  can  be  one  of these  strategies.  Through  WGS  we can assess 
sequencing (WGS) that provides insights into the virulence and resistance mechanisms 
rapidly emerging strains will be of direct benefit for the patient. The use of whole genome 
and better understanding the mechanisms of virulence, resistance and dissemination of 
use of currently available antibiotics. Thus, new, rapid molecular diagnostic techniques 
E. coli. This can only be achieved by improving diagnostic methods and the most prudent 
management of UTIs in patients, especially in cases were infections are caused by MDR 
E. coli have led to serious and difficult-to-treat infections. There is a need to improve the 
costs. Particularly, UTIs are one of  the most common HA-infections. MDR-bacteria as 
leading  to  an  increase in  morbidity  and  mortality as  well as  an  increase in  health  care 
In general, infections inside hospitals are considered a public health problem in Brazil 
Research questions and scope of  the thesis










profile affect the susceptibility of  bacterial cells to antibiotics in biofilms??
molecular  mechanisms  associated  with  this  phenotype?  and  Can  a  heteroresistance 
fosfomycin heteroresistance among our multidrug resistant E. coli isolates? What are the 
Therefore, the next questions addressed in this thesis were: What is the frequency of 
oresistance and its definition and methodologies to study it are not standardized.
with  recurrent  infections. However, there  are  only few studies about fosfomycin heter- 
high concentrations of antibiotics can lead to therapy failure  and  could  be associated 
topic. In heteroresistant populations, subpopulations able to growth in the presence of 
this antibiotic, i.e., heteroresistance against it, that, as mentioned, is a poorly investigated 
fosfomycin remaining low, another phenomenon could lead to reduced susceptibility to 
fosfomycin against this pathogen with low resistance rates. Despite the resistance rate of 
plicated UTIs caused by MDR bacteria. Previous studies showed a high effectiveness of 
antibiotics, such as fosfomycin have been studied as an alternative option to treat com- 
As the treatment of UTIs caused by multidrug-resistant E. coli is at least challenging, old 
virulence of  the isolates.
reveal the role of  MGEs in the antimicrobial resistance and 
urine of  hospitalized patients, in Rio de Janeiro, Brazil and to 
ent in ST131 E. coli isolates and  other  lineages  isolated  from 
which had as main objectives to characterize the MGEs pres- 
We tried to answer these questions in chapter 3 of  this thesis 
ST131 isolates?
these isolates? And Is there an association between plasmids and specific sub-clones of 
isolates? What  is  the  role  of  these  MGEs  in  the  virulence  and  resistance  profiles  of 
Therefore,  our  next  questions  were:  Which  MGEs  can  be  identified  in  our E.  coli 
virulent and associated with complicated UTIs.
known  to  drive  the  evolution  towards  specific  sub-clones  of E.  coli that  are  more 
is associated with the emergence of  high-risk E. coli clones. Furthermore, plasmids are 
tion of plasmids is known as the main mechanism to acquire antibiotic resistance and 
host defense mechanisms and to cause more severe infections. In addition, the acquisi- 
dramatically  increase  the  virulence  genes  content  allowing  these  bacteria  to  overcome 
genomic islands, particularly PAIs, horizontally transferred between bacterial cells, can 
to drive the evolution of specific successful lineages spread worldwide. Among MGEs, 
MGEs play an important role in the virulence and resistance of E. coli and are known 
 Chapter 1
We addressed these questions in chapter 4 of this thesis 
which had as main objectives to study the frequency of 
heteroresistance in E. coli isolated from urine of hospitalized 
patients in Brazil, to characterize the possible molecular 
mechanisms involved in it and to investigate the potential 
effect of the heteroresistance in the eradication of  (bacteria 
in) biofilms.
As mentioned, virulence factors are essential for E. coli pathogenesis. Bacteriocins are a 
group of  antibacterial peptides produced by bacteria that allow them to kill other close-
ly related bacteria. They are one of  the virulence factors that can increase the survival 
of  bacteria by increasing their competitiveness. Bacteriocins are frequently encoded by 
plasmids and are produced by both commensal and pathogenic E. coli including those 
present in the human gut microbiota. Bacteriocins could help specific lineages to colo-
nize the human gut making it a reservoir for these pathogens that then can cause UTIs by 
contaminating the urinary tract. However, the number and types of bacteriocins present 
in E. coli isolates is extremely diverse and until now no indication of specific bacteriocin 
genes associated with resistant lineages was found. Nonetheless, the presence of bacterio-
cin and resistance genes on the same plasmid can enhance the spread of specific bacte-
riocin genes among lineages associated with antibiotic resistance. Hence, the questions 
addressed in this chapter were: Could the presence of  plasmids encoding bacteriocin and 
resistance genes affect the virulence potential of  bacteria? and Could the presence of 
resistance genes in bacteriocin encoding plasmids enhance transmission of  this plasmid?
These questions were addressed in chapter 5 of  this thesis 
which had as main objectives to characterize resistance genes 
and colicin-encoding plasmids of  ST131 E. coli isolated from 
clinical urine samples and to investigate their role in the viru-
lence of  these isolates.
Virulence factors such as adhesins, invasins, iron uptake systems and biofilm-
forming ability are essential in the pathogenesis of E. coli as they allow the bacteria to 
colonize and survive in the host. The biofilm-forming ability is associated with chronic 
and device-related UTIs. However, the presence of  resistance and virulence 
determinants in E. coli isolates represent only half  of  the factors that contribute to the 
risk of  developing a UTI; the other half is related to the host’s susceptibility. The 
presence of several risk factors is 
17
Research questions and scope of the thesis 
known to increase the host susceptibility and the risk of  therapeutic failure. Despite sev-
eral studies have been performed to better understand the relation between the genetic 
characterization of pathogens and the risk factors in patients suffering from UTIs, the 
genotypic diversity among ExPEC strains makes it difficult to find such associations 
and more studies are required to get a better understanding of it.
Therefore, our next questions were: Could we correlate the biofilm-forming ability with 
virulence and resistance phenotypes and genotypes? and Is there an association between 
the pathogenicity of  the bacteria and the presence of  risk factors of  the patients?
These questions were addressed in chapter 6 of  this thesis 
which had as main objective to reveal characteristics of  UTIs 
in hospitalized patients in Rio de Janeiro, Brazil, including 
the biofilm-forming ability and antibiotic susceptibility of  the 
bacteria, the presence of  bacterial virulence and resistance 
genes, and a possible correlation between the patient’s risk 
factors and getting a CA-UTI or HA-UTI.
Finally, in the chapter 7 of this thesis we discuss our findings, try to make conclusions 







Urinary tract infection/male genital infection,” Journal of  Infection and Chemotherapy, vol. 23, no. 11, pp. 733–
[19]S. Yamamoto et al., “JAID/JSC Guidelines for Clinical Management of  Infectious Disease 2015 − 
cine, vol. 167, no. 7, pp. ITC49–ITC64, 2017.
[18]K. Gupta, L. Grigoryan, and B. Trautner, “In the clinic urinary tract infection,” Annals of  Internal Medi- 
observational retrospective multicentric study in Turkey,” Clinical Microbiology and Infection, 2015.
[17]N. Saltoglu et al., “Predictors for limb loss among patient with diabetic foot infections: An
2016.
automated monitoring of  hospital-acquired infection,” Journal of  Hospital Infection, vol. 92, no. 4, pp. 397–400, 
[16]J. D. Redder, R. A. Leth, and J. K. Møller, “Analysing risk factors for urinary tract infection based on 
no. 1, pp. 13–27, 2012.
[15]L. E. Nicolle, “Urinary Catheter-Associated Infections,” Infectious Disease Clinics of  North America, vol. 26, 
Advanced Nursing, vol. 75, no. 3, pp. 517–527, 2019.
tion among hospitalized patients: A systematic review and meta-analysis of observational studies,” Journal of 
[14]F. Li, M. Song, L. Xu, B. Deng, S. Zhu, and X. Li, “Risk factors for catheter-associated urinary tract infec- 
Drugs & Aging, vol. 31, no. 1, pp. 1–10, 2014.
[13]L. E. Nicolle, “Catheter-Related Urinary Tract Infection: Practical Management in the Elderly,”
Spectrum, vol. 4, no. 5, pp. 3–27, 2016.
[12]S. Geerlings, “Clinical presentation and epidemiology of  urinary tract infections,” Microbiology
26–59, 2008.
nary tract infections due to Escherichia coli and Proteus mirabilis,” Clinical Microbiology Reviews, vol. 21, no. 1, pp.
[11]S. M. Jacobsen, D. J. Stickler, H. L. T. Mobley, and M. E. Shirtliff, “Complicated catheter-associated uri- 
PlosOne, pp. 1–10, 2018.
urinary-tract infections , associated antibiotics and the risk of  developing prostate cancer using PCBaSe,” 
[10]J. Adolfsson, B. Russell, H. Garmo, K. Beckmann, and M. Van Hemelrijck, “A case-control study of  lower 
45–59, 2015.
[9]S. Kumar, A. Dave, B. Wolf, and E. V. Lerma, “Urinary tract infections,” Disease-a-Month, vol. 61, no. 2, pp. 
Infection: Future Considerations,” European Urology, Supplements, vol. 15, no. 4, pp. 71–80, 2016.
[8]V. Smelov, K. Naber, and T. E. Bjerklund Johansen, “Improved Classification of  Urinary Tract
with complicated urinary tract infection,” Journal of  Infection, vol. 76, no. 2, pp. 121–131, 2018.
[7]S. Karve et al., “The impact of  initial antibiotic treatment failure: Real-world insights in patients
Clinical Infectious Diseases, vol. 68, no. 1, pp. 29–36, 2019.
complicated urinary tract infection: A multicenter retrospective cohort study (RESCUING study group),” 
[6]N. Eliakim-Raz et al., “Risk factors for treatment failure and mortality among hospitalized patients with 
Practice, vol. 40, no. 3, pp. 687–706, 2013.
[5]A. Wang, P. Nizran, M. A. Malone, and T. Riley, “Urinary tract infections,” Primary Care - Clinics in Office 
infection, and spinal cord injury,” Infectious Disease Clinics of  North America, vol. 28, no. 1, pp. 91– 104, 2014.
[4]L. E. Nicolle, “Urinary tract infections in special populations. diabetes, renal transplant, HIV
recurrence characteristics,” Brazilian Journal of  Infectious Diseases, vol. 20, no. 1, pp. 19–25, 2016.
2 months of  age with urinary tract infection in Southern Israel: Epidemiologic, microbiologic and disease 
[3]E. Gurevich, D. Tchernin, R. Schreyber, R. Muller, and E. Leibovitz, “Follow-up after infants younger than 
era of  antimicrobial resistance,” Postgraduate Medicine, vol. 129, no. 2, pp. 242–258, 2017.
[2]M. S. Bader, M. Loeb, and A. A. Brooks, “An update on the management of  urinary tract infections in the 
vol. 131, pp. 177–189, 2016.
as an adherence factor involved in biofilm formation and binding to uroepithelial cells,” Journal of  Proteomics, 
proteomics of  uropathogenic Escherichia coli during growth in human urine identify UCA-like (UCL) fimbriae 







[41]M. F. Azpiroz, M. E. Poey, and M. Laviña, “Microcins and urovirulence in Escherichia coli,” Microbial Patho-
Infectious Diseases, vol. 35, no. 4, pp. 571–578, 2016.
heteroresistant Escherichia coli infections in Southwest China,” European Journal of  Clinical Microbiology and 
[40]W. Ma, J. Sun, S. Yang, and L. Zhang, “Epidemiological and clinical features for cefepime
Their Bacteriocins for Therapeutics,” Trends in Microbiology, vol. 27, no. 8, pp. 690–702, 2019.
[39]P. Hols, L. Ledesma-García, P. Gabant, and J. Mignolet, “Mobilization of  Microbiota Commensals and 
2007.
[38]E. Cascales et al., “Colicin Biology,” Microbiology and Molecular Biology Reviews, vol. 71, no. 1, pp. 158–229, 
Annual Review of  Microbiology, vol. 44, pp. 395–427, 1990.
[37]L. C. Vining, “Functions of  Secondary Structural Complexity of  Secondary Metabolites Waste Products,” 
Reviews of  biophysics, vol. 45, no. 1. 2012.
[36]G. Papadakos, J. A. Wojdyla, and C. Kleanthous, “Nuclease colicins and their immunity proteins”, Quartely 
virulence factor,” BMC Microbiology, vol. 10, 2010.
ŠŠmajs et al., “Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: Colicin E1 is a potential 
virulence genes by subtractive cloning.,” The Journal of  infectious diseases, vol. 183 Suppl, pp. S21-3, 2001.[35]D. 
[34]F. K. Bahrani-Mougeot, S. Pancholi, M. Daoust, and M. S. Donnenberg, “Identification of  putative uro- 
International Journal of  Antimicrobial Agents, vol. 22, no. SUPPL. 2, 2003.
[33]L. Emody, M. Kerényi, and G. Nagy, “Virulence factors of  uropathogenic Escherichia coli,”
Resistant Subpopulation of  Bacterial Cells,” PLoS ONE, vol. 8, no. 7, 2013.
[32]O. M. El-Halfawy and M. A. Valvano, “Chemical Communication of  Antibiotic Resistance by a Highly 
vol. 17, no. 7, pp. 1039–1043, 2011.
spectrum β-lactamase-producing Escherichia coli from Rio de Janeiro, Brazil,” Clinical Microbiology and Infection, 
[31]G. Peirano, M. D. Asensi, A. Pitondo-Silva, and J. D. D. Pitout, “Molecular characteristics of  extended- 
hospitals in Rio de Janeiro, Brazil.,” Journal of  clinical microbiology, vol. 40, no. 7, pp. 2420–4, 2002.
[30]F. L. P. C. Pellegrino et al., “Occurrence of  a multidrug-resistant Pseudomonas aeruginosa clone in different 
development of  urinary tract infection and kidney damage,” International Journal of  Nephrology, vol. 2012, 2012.
[29]J. Bien, O. Sokolova, and P. Bozko, “Role of  uropathogenic Escherichia coli virulence factors in
vol. 8, 2017.
lence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies,” Frontiers in Microbiology, 
[28]M. E. Terlizzi, G. Gribaudo, and M. E. Maffei, “UroPathogenic Escherichia coli (UPEC) infections: Viru- 
Urogenital Tract Infection, vol. 10, no. 2, p. 57, 2015.
[27]S. Y. Choi and I. H. Chang, “Molecular Defense Mechanisms during Urinary Tract Infection,”
era of  antimicrobial resistance,” Postgraduate Medicine, vol. 129, no. 2, pp. 242–258, 2017.
[26]M. S. Bader, M. Loeb, and A. A. Brooks, “An update on the management of  urinary tract infections in the 
infections,” Iranian Journal of  Microbiology, vol. 2, no. 2, pp. 59–72, 2010.
[25]M. Katouli, “Population structure of  gut Escherichia coli and its role in development of  extra- intestinal 
data gaps,” Frontiers in Microbiology, vol. 6, no. FEB, pp. 1–9, 2015.
[24]R. S. Singer, “Urinary tract infections attributed to diverse ExPEC strains in food animals: Evidence and 
6–13, 2016.
challenges for vaccine development and progress in the field,” Journal of  Infectious Diseases, vol. 213, no. 1, pp.
[23]J. T. Poolman and M. Wacker, “Extraintestinal pathogenic Escherichia coli, a common human pathogen:
ion in Infectious Diseases, vol. 29, no. 1, pp. 73–79, 2016.
[22]Z. Tandogdu and F. M. E. Wagenlehner, “Global epidemiology of  urinary tract infections,” Current Opin- 
Escherichia coli clinical isolates,” Chemotherapy, vol. 59, no. 5, pp. 379–384, 2014.
[21]N. Tsukamoto et al., “High prevalence of  cross-resistance to aminoglycosides in fluoroquinolone-resistant 
10, no. 1, pp. 1–9, 2018.
serum resistance in some strains of  pandemic sequence types without overall fitness cost,” Gut Pathogens, vol. 
[20]A. Ranjan et al., “ESBL-plasmid carriage in E. coli enhances in vitro bacterial competition fitness and 
751, 2017.
Chapter 1
genesis, vol. 47, no. 5, pp. 274–280, 2009.
[42]L. Micenková et al., “Bacteriocin-encoding genes and ExPEC virulence determinants are associated in 
human fecal Escherichia coli strains,” BMC Microbiology, vol. 14, no. 1, pp. 1–9, 2014.
[43]M. Budič, M. Rijavec, Ž. Petkovšek, and D. Žgur-Bertok, “Escherichia coli bacteriocins: Antimicrobial effi-
cacy and prevalence among isolates from patients with bacteraemia,” PLoS ONE, vol. 6, no. 12, 2011.
[44]L. Micenková, J. Bosák, M. Vrba, A. Ševčíková, and D. Šmajs, “Human extraintestinal pathogenic Esche-
richia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants,” BMC 
Microbiology, vol. 16, no. 1, pp. 1–8, 2016.
[45]A. E. Barber, J. P. Norton, A. M. Spivak, and M. A. Mulvey, “Urinary tract infections: Current and 
emerging management strategies,” Clinical Infectious Diseases, 2013.
[46]M. Tabasi, M. R. Asadi Karam, M. Habibi, M. S. Yekaninejad, and S. Bouzari, “Phenotypic Assays to 
Determine Virulence Factors of Uropathogenic Escherichia coli (UPEC) Isolates and their
Correlation with Antibiotic Resistance Pattern,” Osong Public Health and Research Perspectives, vol. 6, no. 4, pp. 
261–268, 2015.
[47]T. Cai et al., “Prostate calcifications : A case series supporting the microbial biofilm theory,” Investigative and 
Clinical  Urology, pp. 187–193, 2018.
[48]R. Bartoletti et al., “The impact of biofilm-producing bacteria on chronic bacterial prostatitis
treatment : results from a longitudinal cohort study,” World Journal of Urology, pp. 737–742, 2014.
[49]S. M. Soto, “Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches,” Advances 
in Biology, vol. 2014,ID543974,  2014.
[50]W. Adamus-Białek and Anna Kubiak and Grzegorz Czerwonka, “Analysis of uropathogenic
Escherichia coli biofilm formation under different growth conditions,” Biochimica Polonica, vol. 62, pp. 765–771, 
2015.
[51]A. R. Eberly et al., “Biofilm formation by uropathogenic Escherichia coli is favored under oxygen condi-
tions that mimic the bladder environment,” International Journal of Molecular Sciences, vol. 18, no. 10, pp. 1–12, 
2017.
[52]D. Piljic, H. Porobic-Jahic, D. Piljic, S. Ahmetagic, and R. Jahic, “Chateter-associated Urinary Tract 
Infections in Adults.,” Materia socio-medica, vol. 25, no. 3, pp. 182–6, 2013.
[53]S. M. Soto, A. Smithson, J. P. Horcajada, J. A. Martinez, J. P. Mensa, and J. Vila, “Implication of biofilm
formation in the persistence of urinary tract infection caused by uropathogenic   Escherichia coli,” Clinical Micro-
biology and Infection, vol. 12, no. 10, pp. 1034–1036, 2006.
[54]M. A. Croxen and B. B. Finlay, “Molecular mechanisms of Escherichia coli pathogenicity,” Nature Reviews, 
vol. 8, no. January, 2010.
[55]H. M. Zowawi et al., “The emerging threat of multidrug-resistant Gram-negative bacteria in
urology. [Review],” Nature Reviews Urology, 2015.
[56]A. Flores-Meireles et al., “Urinary tract infections: epidemiology, mechanisms of infection and treatment 
options,” Nature reviews Microbiology, vol. 13, no. 5, pp. 269–284, 2015.
[57]M. A. M. Adam J. Lewis, Amanda C. Richards, “Invasion of Host Cells and Tissues by Uropathogenic 
Bacteria,” Microbiology Spectrum, vol. 0026, pp. 2–29, 2017.
[58]P. S. Cyoia et al., “Presence of virulence genes and pathogenicity islands in extraintestinal pathogenic 
Escherichia coli isolates from Brazil,” Journal of Infection in Developing Countries, vol. 9, no. 10, pp. 1068–1075, 2015.
[59]L. C. Da Silva, A. C. De Mello Santos, and R. M. Silva, “Uropathogenic Escherichia coli pathogenicity is-
lands and other ExPEC virulence genes may contribute to the genome variability of enteroinvasive E. coli,”
BMC Microbiology, vol. 17, no. 1, pp. 1–8, 2017.
[60]E. Bozcal, “Insight into the mobilome of Escherichia coli,” IntechOpen, vol. 3, no. 1, pp. 198–210, 2016.
[61]C. Bertelli, K. E. Tilley, and F. S. L. Brinkman, “Microbial genomic island discovery, visualization and 
analysis,” Briefings in Bioinformatics, no. February, pp. 1–14, 2018.





[82]N. Fam et al., “CTX-M-15-Producing Escherichia coli Clinical Isolates in Cairo (Egypt), Including Isolates
coli from community-acquired urinary tract,’” BMC Microbiology, vol. 16, no. 1, pp. 2–7, 2016.
[81]F. B. Hertz et al., “‘population structure of  drug-susceptible, - Resistant and ESBL-producing Escherichia 
tion, vol. 20, no. 5, pp. 380–390, 2014.
[80]L. W. Riley, “Pandemic lineages of  extraintestinal pathogenic Escherichia coli,” Clinical Microbiology and Infec- 
Producing,” mSphere, vol. 1, no. 5, pp. 1–13.
[79]T. Miyoshi-akiyama et al., “Comparative Genome Analysis of  Extended-Spectrum-Lactamase-
Using Evolutionary and Epidemiological Genomics,” Microorganisms, vol. 3, no. 2, pp. 236– 267, 2015.
[78]T. Downing, “Tackling Drug Resistant Infection Outbreaks of  Global Pandemic Escherichia coli ST131 
58, no. 7, pp. 3762–3767, 2014.
trum β-lactamases: Global distribution of  the H30-Rx sublineage,” Antimicrobial Agents and Chemotherapy, vol. 
[77]G. Peirano et al., “Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spec- 
Clinical Microbiology Reviews, vol. 27, no. 3, pp. 543–574, 2014.
[76]M. H. Nicolas-Chanoine, X. Bertrand, and J. Y. Madec, “Escherichia coli ST131, an intriguing clonal group,” 
National Academy of  Sciences, vol. 111, no. 15, pp. 5694–5699, 2014.
[75]N. K. Petty et al., “Global dissemination of  a multidrug resistant Escherichia coli clone,” Proceedings of  the 
resistance in Escherichia coli,” Expert Review of  Molecular Diagnostics, vol. 18, no. 3, pp. 207–217, 2018.
[74]M. E. Fleece, S. Pholwat, A. J. Mathers, and E. R. Houpt, “Molecular diagnosis of  antimicrobial
al Agents and Chemotherapy, vol. 58, no. 11, pp. 6886–6895, 2014.
Escherichia coli sequence type 131 clonal group and its H30 and H30-Rx Subclones, 1968 to 2012,” Antimicrobi- 
[73]B. Olesen et al., “Temporal trends in antimicrobial resistance and virulence-associated traits within the 
ternational Multiresistant High-Risk Clone, vol. 90. Elsevier Ltd, 2015.
[72]A. J. Mathers, G. Peirano, and J. D. D. Pitout, Escherichia coli ST131: The Quintessential Example of  anIn- 
Updates, vol. 17, no. 1–2, pp. 24–36, 2014.
South America: History, current dissemination status and associated socioeconomic factors,” Drug Resistance 
[71]R. R. Bonelli, B. M. Moreira, and R. C. Picão, “Antimicrobial resistance among Enterobacteriaceae in 
Journal of  Global Antimicrobial Resistance, vol. 6, pp. 1–4, 2016.
Escherichia coli causing community-acquired urinary tract infection in the Central- Western Region, Brazil,” 
[70]L. F. Gonçalves et al., “Multidrug resistance dissemination by extended-spectrum β-lactamase- producing 
therapy in Serbia,” Journal of  Infection in Developing Countries, vol. 10, no. 10, pp. 1065– 1072, 2016.
[69]S. Zec et al., “Antimicrobial resistance in patients with urinary tract infections and the impact on empiric 
monwealth no. May, 2016.
Review On Antimicrobial Resistance,” UK  Department of  Heathy HM Treasury, and the Foreign and Com- 
[68]J. I. M. O. Neill, “Tackling Drug-Resistant Infections Globally:Final Report And Recommendations The 
no. 3, pp. 565–591, 2015.
high- risk clones in the spread of  multidrug-resistant Enterobacteriaceae,” Clinical Microbiology Reviews, vol. 28, 
[67]A. J. Mathers, G. Peirano, and J. D. D. Pitout, “The role of  epidemic resistance plasmids and international 
es,” PLoS ONE, vol. 6, no. 8, 2011.
tance-encoding incA/C plasmids from commensal and pathogenic Escherichia coli from multiple animal sourc- 
[66]C. Fernández-Alarcón, R. S. Singer, and T. J. Johnson, “Comparative genomics of  multidrug resis-
of  uropathogenic Escherichia coli isolates,”Folia Microbiologica, pp. 335–343, 2018.
[65]A. Naja. “Distribution of  pathogenicity island markers and virulence factors in new phylogenetic groups 
World Journal of  Gastroenterology, vol. 11, no. 37, pp. 5816–5820, 2005.
patients with high-pathogenicity island of  Yersinia is involved in synthesis of  siderophore yersiniabactin,” 
[64]J. Hu, B. Kan, Z. H. Liu, and S. Y. Yu, “Enteroaggregative Escherichia coli isolated from Chinese diarrhea 
microbiotas,” Applied and Environmental Microbiology, vol. 77, no. 7, pp. 2303–2308, 2011.
virulence determinants malX and usp, and the capacity of Escherichia coli to persist in infants’ commensal 
[63]A. Östblom, I. Adlerberth, A. E. Wold, and F. L. Nowrouzian, “Pathogenicity island markers,
islands in Escherichia coli using next-generation sequencing,” PLoS ONE, vol. 12, no. 7, pp. 1–17, 2017.
Chapter 1
23
Microbiology, vol. 17, no. July, pp. 441–448, 2019.
[101]N. Q. Balaban et al., “Definitions and guidelines for research on antibiotic persistence,” Nature Reviews 
504–514, 2019.
sistance in pathogenic bacteria is mainly caused by gene amplification,” Nature Microbiology, vol. 4, no. 3, pp. 
[100]H. Nicoloff, K. Hjort, B. R. Levin, and D. I. Andersson, “The high prevalence of  antibiotic heterore- 
lococcus aureus in biofilms,” Journal of  Antimicrobial Chemotherapy, vol. 67, no. 4, pp. 944– 950, 2012.
[99]H. J. Tang et al., “In vitro efficacy of  fosfomycin-containing regimens against methicillin-resistant Staphy- 
vitro dynamic bladder infection model,” Journal of  Antimicrobial Chemotherapy, vol. 73, no. 3, pp. 709–719, 2018. 
[98]I. J. Abbott et al., “Fosfomycin efficacy and emergence of  resistance among Enterobacteriaceae in an in 
Characteristics and Outcomes,” Chemotherapy, vol. 62, no. 2, pp. 100–104, 2017.
Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient
[97]S. E. Giancola, M. V. Mahoney, M. D. Hogan, B. R. Raux, C. McCoy, and E. B. Hirsch, “Assessment of 
drug-Resistant Gram-Negative Pathogens,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 12, pp. 1–8, 2017. 
and Y. Doia, “Inhibition of  Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multi- 
[96]A. Ryota Ito, a Adam D. Tomich, A. Christi L. McElheny, a Roberta T. Mettus, B. Nicolas Sluis-Cremer, a, 
Mechanism of  the Genomically Encoded Fosfomycin Resistance,”Biochemistry, pp. 8110–8120, 2007.
[95]K. L. Fillgrove, S. Pakhomova, M. R. Schaab, M. E. Newcomer, and R. N. Armstrong, “Structure and 
of  Acquired and Intrinsic Fosfomycin Resistance,” Antibiotics, vol. 2, no. 2, pp. 217–236, 2013.
[94]A. Castañeda-García, J. Blázquez, and A. Rodríguez-Rojas, “Molecular Mechanisms and Clinical Impact
2, pp. 1–12, 2017.
[93]L. L. Silver, “Fosfomycin: Mechanism and resistance,” Cold Spring Harbor Perspectives in Medicine, vol. 7, no.
intrinsic resistance to fosfomycin,” Microbial Drug Resistance, vol. 20, no. 3, pp. 231– 237, 2014.
[92]M. Borisova, J. Gisin, and C. Mayer, “Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates 
reviews, vol. 29, no. 2, pp. 321–347, 2016.
[91]M. E. Falagas, E. K. Vouloumanou, G. Samonis, and K. Z. Vardakas, “Fofomycin,” Clinical micro- biology 
the murA1 gene,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 6, pp. 2801– 2808, 2013.
[90]H. Engel et al., “Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on 
269–285, 2016.
fosfomycin: a systematic review of  the literature,” International Journal of  Antimicrobial Agents, vol. 47, no. 4, pp. 
[89]K. Z. Vardakas, N. J. Legakis, N. Triarides, and M. E. Falagas, “Susceptibility of  contemporary isolates to 
Chemotherapy, vol. 70, no. 11, pp. 3042–3050, 2015.
pharmacodynamics of  fosfomycin against clinical isolates of Pseudomonas aeruginosa,” Journal of  Antimicrobial 
[88]C. C. Walsh, M. P. McIntosh, A. Y. Peleg, C. M. Kirkpatrick, and P. J. Bergen, “In vitro
Microbiology Insights, vol. 9, p. MBI.S29459, 2016.
[87]N. Yaneja and H. Kaur, “Insights into Newer Antimicrobial Agents against Gram-negative Bacteria,” 
Therapy, vol. 4, no. 4, pp. 433–458, 2015.
of  the Literature and Analyses of  the FDA Adverse Event Reporting System Database,” Infectious Diseases and 
[86]D. Iarikov, R. Wassel, J. Farley, and S. Nambiar, “Adverse Events Associated with Fosfomycin Use: Review 
125–131, 2016.
resistant and extended spectrum β-lactamase producing strains,” Iranian Journal of  Microbiology, vol. 8, no. 2, pp. 
“Fosfomycin, interesting alternative drug for treatment of  urinary tract infections created by multiple drug 
[85]F. Yeganeh-Sefidan, R. Ghotaslou, M. T. Akhi, M. R. Sadeghi, Y. Mohammadzadeh-Asl, and H. B. Baghi,
transfer of  resistance genes mediated by plasmids in E. coli,” Biotech, vol. 8, no. 5, p. 224, 2018.
[84]L. Song, X. Wang, W. Zhang, L. Ye, and X. Feng, “Low-intensity ultrasound promotes the horizontal 
Escherichia coli sequence type 131.,” mSphere, vol. 1, no. 4, pp. e00121-16, 2016.
[83]T. J. Johnson et al., “Separate F-type plasmids have shaped the evolution of  the H30 subclone of 
Microbial Drug Resistance, vol. 17, no. 1, pp. 67–73, 2011.




and Infection, vol. 23, no. 5, pp. 325–331, 2017.
discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae,” Clinical Microbiology
[106]M. Ballestero-Téllez et al., “Role of  inoculum and mutant frequency on fosfomycin MIC
Treatment Failure in a Murine Model of  Infection,” mBio, vol. 9, no. 2, pp. e02448-17, 2018.
Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to
[105]V. I. Band, S. W. Satola, E. M. Burd, M. M. Farley, J. T. Jacob, and D. S. Weiss, “Carbapenem-Resistant 
Microbiology and Infection, vol. 21, no. 5, pp. 469.e1-469.e10, 2015.
eroresistance among clinical isolates of  invasive Escherichia coli in Chongqing, southwestern China,” Clinical 
[104]J. D. Sun, S. F. Huang, S. S. Yang, S. L. Pu, C. M. Zhang, and L. P. Zhang, “Impact of  carbapenem het- 
pathogens, vol. 15, no. 6, p. e1007726, 2019.
[103]V. I. Band and D. S. Weiss, “Heteroresistance: A cause of  unexplained antibiotic treatment failure?,”PLoS 
clarity,” Clinical Microbiology Reviews, vol. 28, no. 1, pp. 191–207, 2015.
[102]O. M. El-Halfawy and M. A. Valvano, “Antimicrobial heteroresistance: An emerging field in need of 

